US 11,833,270 B2
Xenotransplantation products and methods
Paul W. Holzer, Enfield, NH (US); Jon Adkins, Londonderry, NH (US); Rodney L. Monroy, North Fort Myers, FL (US); and Elizabeth J. Chang, Pittsford, NY (US)
Assigned to XENOTHERAPEUTICS, INC., Grantham, NH (US)
Filed by XENOTHERAPEUTICS, INC., Boston, MA (US); and XENOTHERAPEUTICS CORPORATION, Enfield, NH (US)
Filed on Jun. 14, 2021, as Appl. No. 17/347,077.
Application 17/347,077 is a continuation of application No. 17/017,002, filed on Sep. 10, 2020, granted, now 11,129,922.
Application 17/017,002 is a continuation of application No. 16/593,785, filed on Oct. 4, 2019, granted, now 10,799,614.
Claims priority of provisional application 62/848,272, filed on May 15, 2019.
Claims priority of provisional application 62/823,455, filed on Mar. 25, 2019.
Claims priority of provisional application 62/795,527, filed on Jan. 22, 2019.
Claims priority of provisional application 62/792,282, filed on Jan. 14, 2019.
Claims priority of provisional application 62/756,977, filed on Nov. 7, 2018.
Claims priority of provisional application 62/756,925, filed on Nov. 7, 2018.
Claims priority of provisional application 62/756,993, filed on Nov. 7, 2018.
Claims priority of provisional application 62/756,955, filed on Nov. 7, 2018.
Claims priority of provisional application 62/742,188, filed on Oct. 5, 2018.
Prior Publication US 2021/0308325 A1, Oct. 7, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A01K 67/027 (2006.01); A61L 27/36 (2006.01)
CPC A61L 27/362 (2013.01) [A61L 27/3604 (2013.01); A61L 27/3687 (2013.01); A61L 27/3691 (2013.01)] 22 Claims
 
1. A non-wild type, biologically engineered swine for producing live cells and tissue that vascularize after xenotransplantation,
wherein said swine has a biologically engineered genome such that it does not express one or more extracellular surface glycan epitopes,
wherein said swine is free of at least the following zoonotic pathogens:
(i) Ascaris species, cryptosporidium species, Echinococcus, Strongyloids sterocolis, and Toxoplasma gondii in fecal matter;
(ii) Leptospira species, Mycoplasma hyopneumoniae, porcine reproductive and respiratory syndrome virus (PRRSV), pseudorabies, transmissible gastroenteritis virus (TGE)/Porcine Respiratory Coronavirus, and Toxoplasma Gondii as determined by antibody titers;
(iii) Porcine Influenza;
(iv) the following bacterial pathogens as determined by bacterial culture: Bordetella bronchisceptica, Coagulase-positive staphylococci, Coagulase-negative staphylococci, Livestock-associated methicillin resistant Staphylococcus aureus (LA MRSA), Microphyton and Trichophyton spp.;
(v) Porcine cytomegalovirus; and
(vi) Brucella suis;
wherein said swine has been maintained according to a bioburden-reducing procedure in an isolated closed herd,
wherein all other animals in the isolated closed herd have been confirmed to be free of said zoonotic pathogens, and
wherein the swine was isolated from contact with any non-human animals and animal housing facilities outside of the isolated closed herd.